CAR-T play­er Po­sei­da march­es on with $30.5M Se­ries B; Kymera inks dis­cov­ery deal with GSK

→ In­vestors have in­fused $30.5 mil­lion in Se­ries B cash in­to Po­sei­da Ther­a­peu­tics’ pipeline of au­tol­o­gous T cell and NK cell ther­a­pies. Us­ing its gene en­gi­neer­ing tech, the San Diego com­pa­ny has iden­ti­fied sev­er­al CAR-T and gene ther­a­pies, with the lead pro­gram, P-BC­MA-101 for mul­ti­ple myelo­ma, cur­rent­ly in a Phase I tri­al. The new round of fi­nanc­ing will go to­wards that study, and push Po­sei­da to­ward INDs for two pro­grams in PS­MA CAR-T and al­lo­genic BC­MA CAR-T. Lon­gi­tude Cap­i­tal led the round, flanked by fel­low new in­vestors Vi­vo Cap­i­tal and the Tavi­s­tock Group, and David Hirsch — its man­ag­ing di­rec­tor — will join Po­sei­da’s board of di­rec­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER